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Abstract
In acute lymphoblastic leukemia (ALL) patients, the bone marrow niche is widely known to be an important element of
treatment response and relapse. Furthermore, a characteristic liver pathology observed in ALL patients implies that the
hepatic microenvironment provides an extramedullary niche for leukemic cells. However, it remains unclear whether the
liver actually provides a specific niche. The mechanism underlying this pathology is also poorly understood. Here, to answer
these questions, we reconstituted the histopathology of leukemic liver by using patients-derived primary ALL cells into
NOD/SCID/Yc
null mice. The liver pathology in this model was similar to that observed in the patients. By using this model,
we clearly demonstrated that bile duct epithelial cells form a hepatic niche that supports infiltration and proliferation of ALL
cells in the liver. Furthermore, we showed that functions of the niche are maintained by the SDF-1/CXCR4 axis, proposing a
novel therapeutic approach targeting the extramedullary niche by inhibition of the SDF-1/CXCR4 axis. In conclusion, we
demonstrated that the liver dissemination of leukemia is not due to nonselective infiltration, but rather systematic invasion
and proliferation of leukemic cells in hepatic niche. Although the contribution of SDF-1/CXCR4 axis is reported in some
cancer cells or leukemic niches such as bone marrow, we demonstrated that this axis works even in the extramedullary
niche of leukemic cells. Our findings form the basis for therapeutic approaches that target the extramedullary niche by
inhibiting the SDF-1/CXCR4 axis.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
malignant disease in children[1]. Although accumulated improve-
ments in treatment regimens have raised the 5-year survival rate to
as high as 80% in pediatric patients[2], a poor prognosis is still
expected for a minority of patients with various risk factors and
those with ALL relapses. In particular, relapsed ALL has an
overall survival rate of only 30%[3].
Recent studies about leukemic cells and niche correlation
highlight the importance of therapeutically targeting the bone
marrow (BM) microenvironment [4,5]. The BM niche provides
survival and growth factors for leukemic cells, modulates their
responses to chemotherapies and may even contribute to the
relapse of the disease. But little is known about the extramedullary
niche of leukemia.
Organ involvement varies with the type of neoplastic cell[6].
Such cells find their own appropriate microenviromental condi-
tions in particular tissues for survival and proliferation[6]. The
widespread involvement of extramedullary organs is characteristic
of leukemia. Although leukemic cells can easily disseminate to all
organs by traveling in the peripheral blood, the most striking
changes are restricted in organs such as the liver and spleen. Even
after leukemic cells seem to disappear after treatment, residual
leukemic cells are thought to be released from BM and
extramedullary niche, eventually causing recurrence of the disease
[7]. Consequently, investigation of the interactions between
leukemic cells and the niche at extramedullary sites is a crucial
component in the management and overcome of leukemia;
however, little is known about the role of extramedullary niche
in harboring leukemic cells. Specifically, whether extramedullary
sites actually provide a specific niche, and the factors responsible
for harboring leukemic cells in extramedullary niche remain
unclear.
We previously developed a novel immunodeficient NOD/
SCID/Yc
null (NOG) mouse that provides significantly better
human hematopoietic cell engraftment in the BM and extramed-
ullary organs than other immunodeficient mice[8,9,10,11], and is
capable of supporting the growth of human neoplastic cells[12]. In
the present study, we introduced a human leukemic mouse
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involvement without pre-conditioning (hereby referred to as the h-
leukemic NOG model). Previous animal xeno-transplantation
models for recapitulating human leukemia required precondition-
ing to avoid graft rejection [13,14]. However, these models are not
appropriate for detailed pathological assessment of extramedullary
microenvironments because preconditioning causes modification
of the microenvironment such as upregulation of SDF-1 [15]. As
the h-leukemic NOG model can reproduce leukemic extramed-
ullary involvement without preconditioning, our approach pro-
vides a more sophisticated and physiological model suitable to
study the interactions between leukemic cells and the host niche.
Leukemic cells preferentially infiltrate the liver, and the
hepatomegaly is detected in as high as 30–50% of acute
lymphoblastic leukemia (ALL) patients at diagnosis[16]. As
hepatopathology of ALL is well characterized[17], but little is
known about the molecular mechanisms that contribute to this
pathology, we have focused on the liver for studying the role of
extramedullary niche in sustaining leukemia.
In this paper, we have demonstrated that hepatomegaly and
pathology in ALL patients are not only due to random infiltration
but rather the result of SDF-1/CXCR4 axis-dependent migration
and expansion of leukemic cells in the hepatic niche. Moreover,
we have succeeded in suppressing post-chemotherapeutic leukemic
regrowth in the hepatic niche by inhibiting the SDF-1/CXCR4
axis, thus resulting in an improvement in the overall survival.
Although the contribution of SDF-1/CXCR4 axis is reported in
some cancer cells [18,19] or leukemic niches such as bone marrow
[20], we demonstrated that this axis works even in the
extramedullary niche of leukemic cells. These results provide a
better understanding of the mechanisms of the extramedullary
dissemination and aid in the development of ALL therapies that
target the extramedullary niche.
Results
Human leukemic cells can be serially reconstituted in
NOG mice without pre-conditioning
To establish a xenograft murine model of human ALL without
damage to the recipient niche (h-leukemic NOG model), we first
injected 1610
6 leukemic cells derived from primary BM of nine
ALL children into the tail veins of untreated NOG mice
(Table 1). Flow cytometric analysis of the BM revealed that eight
of the nine leukemias engrafted in transplanted mice were
detectable three weeks post-transplantation, and that BM
chimerisms reached more than 40% of leukemic cells within
28 weeks in all engrafted cases (Figure 1A and Figure S1).
Sequential H-E staining and immunohistochemical analysis of
ALL #1 leukemic cell-engrafted humeri using anti-hCD45
antibodies demonstrated that hCD45-positive leukemic cells
continued to reside within the BM (Figure 1B). Serial
transplantation of leukemic cells from three representative cases
into secondary and tertiary recipients demonstrated a conserved
morphology (Figure 1C) and characteristic immunophenotypes
(Figure 1D) in NOG mice. These results demonstrate the
potential of our h-leukemic NOG model to recapitulate human
ALL in NOG mice.
Liver pathology in the h-leukemic NOG model resembles
that in leukemic patients
The h-leukemic NOG model showed the development of pale
BM, hepatomegaly, and splenomegaly same as the original patient
(Figure 2A and 2B), which was massively infiltrated with
lymphoblasts (Figure S2). In the analysis of liver pathology, large
clusters of leukemic cells were observed in the portal area of all
cases analyzed (Figure 2C), consistent with the previously reported
pathology of human ALL patients[17]. The same pathological
results were obtained even after the intra-femoral injection of
leukemic cells (Figure 2C).
Sequential analysis showed that small number of leukemic cells
first localized around the bile ducts, and then developed into large
clusters in the portal area. On the other hand, only single cells or
small clusters were scattered throughout the sinusoidal areas
(Figure 2D). These results suggest that our model recapitulates the
histopathology of human ALL leukemic liver. Moreover, the data
strongly indicate some specific mechanism by which portal areas
attract and retain ALL leukemic cells.
Leukemic cells proliferated around liver bile duct
epithelial cells
To confirm whether leukemic cells are proliferating after settling
in the liver, we performed cell cycle analysis of leukemic cells
harvested from the liver, PB, and BM. The liver and BM
contained a substantial fraction of proliferating leukemic cells
(Figure 3A and 3B), while leukemic cells in the PB were
predominantly non-proliferating. In vivo immunohistochemical
staining with BrdU also showed that human CD45- positive
leukemic cells in the liver were in the proliferation phase
(Figure 3C). Interestingly, significantly increased number of BrdU
Table 1. Patient and leukemia characteristics.
Patient ID Age/Gender Source WBC (/ml) BM blast (%) Stage Immunophenotype Cytogenetics
ALL #1 7/M BM 183600 81.5 Diagnosis CD45
+CD10
+CD19
+CD20
- Normal
ALL #2 1/F BM 7700 10 Relapse CD45
+CD10
+CD19
+CD20
partial Normal
ALL #3 4/F BM 10500 91 Diagnosis CD45
-CD10
+CD19
+CD20
- Hyperdiploid
ALL #4 7/M BM 3700 84.7 Diagnosis CD45
+CD10
+CD19
+CD20
partial E2A/PBX
ALL #5 4/F BM 800 43.2 Diagnosis CD45
+CD10
+CD19
+CD20
+ TEL/AML-1
ALL #6 4/M BM 323700 91 Diagnosis CD45
+CD10
+CD19
+CD20
- Hyperdiploid
ALL #7 9/F BM 3800 92.5 Diagnosis CD45
+CD10
+CD19
+CD20
partial TEL/AML-1
ALL #8 2/M BM 4300 75.4 Diagnosis CD45
+CD10
+CD19
+CD20
partial MLL/ENL
ALL #9 8/M BM 29400 70 Diagnosis CD45
+CD10
+CD19
+CD20
partial Normal
M: male. F: female. BM: bone marrow. WBC: white blood cell.
doi:10.1371/journal.pone.0027042.t001
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to that in the sinusoidal areas (Figure 3D). Together, these results
suggest that leukemic cells surrounding the bile ducts are not only
anchored by bile duct epithelial cells, but also undergo
proliferation around the bile duct epithelial cells.
The number of CXCR4 positive leukemic cells was
significantly higher in the liver. Detailed description of
liver pathology revealed the existence of a functional
niche mediated by SDF-1/CXCR4 axis
Previous studies have demonstrated that several adhesion
molecules and chemokines, including CXCR4, CD56, CD44,
CCR7, and VLA-4, contribute to the harboring and proliferation
of leukemic cells in the BM niche and may enhance niche-
mediated resistance in leukemia [21,22,23,24,25]. To identify
molecules involved in the pathology of the ALL leukemic liver, we
analyzed their expression on leukemic cells harvested from the
BM, liver, and spleen, in the three cases listed in Table 1. Flow
cytometric analysis revealed that the percentage of CXCR4-
positive leukemic cells was significantly higher in the liver than that
in other organs (Figure 4A and 4B). Consistent with previous
studies [15,26,27], SDF-1 was expressed on bile duct epithelial
cells in the portal area of the h-leukemic NOG model (Figure 4C).
Immunohistochemical analysis showed that CXCR4 positive
leukemic cells were mainly distributed in the portal area,
surrounding SDF-1 positive bile duct epithelial cells, but not in
the sinusoidal area (Figure 4C). Moreover, proximity ligation assay
confirmed the specific interaction between CXCR4 on leukemic
cells and SDF1 (Figure S3). Therefore, these results strongly
suggest that the SDF-1/CXCR4 axis plays a role in the hepatic
niche of leukemic cells.
The SDF-1/CXCR4 axis stimulates not only migration, but
also proliferation, of ALL leukemic cells in vitro and in vivo
The SDF-1/CXCR4 axis is a key factor in the migration and
proliferation of various cells, including neoplastic cells in vivo
[18,19,28]. Thus, we sought to directly examine the influence of
the SDF-1/CXCR4 axis on leukemic cell migration and
proliferation.
First, we performed a chemotaxis assay by stimulating CXCR4
with its ligand SDF-1 (Figure 5A). Leukemic cells harvested from
the liver migrated avidly in response to SDF-1, and this migration
Figure 1. Leukemic cells can be engrafted to NOG mice without pre-conditioning. Morphology ( May-Grunwald Giemsa staining) and
immunophenotype of leukemic blasts remain stable during serial transplantation in NOG mice. (A) Sequential FACS analyses showing bone marrow
engraftment after transplantation. Graphs show percentage of blast cells (hCD45 or hCD19 positive cells) in recipient BM (n=326 mice per case).Data
are shown as means6S.D. (B) H-E staining and anti-hCD45 immunostaining showing increasing number of leukemic cells over time in the humerus of
ALL#1 leukemic cell-recipient NOG mice. Scale bar, 10 mm. (C) Morphology and (D) immunophenotype of original patient blast cells (left row) and BM
samples derived from murine primary and tertiary transplants of leukemic cells (middle and right rows). Debris (low forward scatter), dead cells (DAPI-
positive), and mouse CD45 positive cells were excluded from analysis. Scale bar, 20 mm.
doi:10.1371/journal.pone.0027042.g001
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that antagonizes the binding of SDF-1 to CXCR4. Moreover, in a
checkerboard assay, cell numbers increased along the positive
SDF-1 gradient in a dose-dependent manner (Figure S4). These
results confirm the effects of SDF-1 on the migration of leukemic
cells.
We next performed a methylcellulose colony-forming assay to
examine the effect of SDF-1/CXCR4 signaling on the prolifer-
ation of leukemic cells harvested from liver(Figure 5B). The
addition of SDF-1 significantly increased the number of colonies,
while treatment with AMD3100 counteracted the effect of SDF-1.
Western blotting revealed that SDF-1 stimulation induced
Figure 2. NOG recipient mice transplanted with ALL cells show a clinical leukemic pathology. (A) CT image of patient ALL#1 abdomen
shows hepatosplenomegaly at diagnosis. (B) Macroscopic hepatosplenomegaly of the NOG recipient mouse transplanted with ALL#1 leukemic cells.
Comparison of gross appearance of organs in normal mice (right-hand side) and leukemic NOG mice transplanted with ALL #1 leukemic cells (left-
hand side). Pale femur and enlarged liver and spleen are shown. Scale bar, 1 cm. (C) In all ALL cases analyzed, the corresponding leukemic NOG
recipients had large clusters of leukemic cells in portal area. Three representative cases of intra-vein injection and one case of intra-femoral injection
are shown. Scale bar, 50 mm. (D) Sequential histopathological analysis of the liver of leukemic NOG mice transplanted with ALL#1 leukemic cells
showed growth of leukemic cell clusters in portal areas (left column), but not sinusoidal areas (right column). Scale bar, 50 mm. pv; portal vein. IV; intra
vein injection. IF; intra femoral injection. Arrowheads indicate bile ducts.
doi:10.1371/journal.pone.0027042.g002
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important mediators of chemotaxis[26] and prolifera-
tion[20,29,30] of several cell types, and these phosphorylation
were suppressed in the presence of AMD3100 (Figure 5C).
Next, we transplanted leukemic cells harvested from BM and
liver, with different populations of CXCR4-positive cells, into
NOG mice and compared the engraftment. Rapid growth of
leukemic cells was observed in NOG mice transplanted with
Figure 3. Human ALL cells preferentially proliferated around bile duct epithelial cells. (A) Frequency of S + G2/M phase leukemic cells in
each organ of the mice (*P=0.019,
# P=0.036, Student’s t-test, compared with leukemic cells in the peripheral blood, n=425). Data are shown as
mean6S.D. (B) Representative FACS panels of cell cycle analysis of leukemic cells in each tissue of the recipient mice. (C) H-E, hCD45, and BrdU
staining of liver sections of h-leukemic NOG model. Bile duct epithelial cells were surrounded by large numbers of hCD45
+ leukemic cells in portal
area (i and ii). A few hCD45
+ leukemic cells were observed as single cells or small clusters randomly distributed in the sinusoidal area (iii). Negative
control (iv). Scale bar, 50 mm. pv; portal vein . Arrowheads indicate bile ducts. (D) Parcentage of BrdU-positive cells among blast cells in the portal and
sinusoidal areas (*P=0.0015, Student’s t- test, n=4). Data are shown as mean6S.D.
doi:10.1371/journal.pone.0027042.g003
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number of CXCR4-positive leukemic cells (Figure 5D).
Taken together, these data indicate that the SDF-1/CXCR4
axis stimulates not only migration but also proliferation of ALL
leukemic cells in vivo and in vitro, and implied the importance of
targeting the extramedullary microenvironment to prevent
recurrence from emerging from minimal residual disease in the
extramedullary microenvironment in ALL patients.
Figure 4. The ratio of CXCR4-positive leukemic cells was significantly higher in the liver. Bile duct epithelial cells were strongly positive
for SDF-1 and surrounded by CXCR4 positive leukemic cells. (A) Relative ratio of percentage in positive cells of CXCR4, CD56, CD44, CCR7, and VLA4
out of leukemic cells harvested from liver and spleen compaired with leukemic cells from BM (*P=0.0099,
#P=0.0091, paired t-test. n=429 mice per
case. ALL#1, #2 and #3 were analyzed). Data are shown as mean6S.D. (B) Representative FACS panels of CXCR4 expression in leukemic cells from
each organ. Leukemic cells in the liver show higher levels of CXCR4 expression than those in the BM. (C) Large number of leukemic cells were
observed in the portal area, and bile duct epithelial cells are strongly positive for SDF-1. CXCR4-positive leukemic cells were present in large numbers
around bile ducts. Portal area (i) and sinusoidal area (ii). Scale 50 mm. pv; portal vein. Arrowheads indicate bile ducts.
doi:10.1371/journal.pone.0027042.g004
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cells surrounding the bile ducts after chemotherapy and
which thus led to the superior survival of the h-leukemic
NOG mice
Finally, we examined the effects of inhibiting SDF-1/CXCR4
axis on leukemic cells in the hepatic niche. A single-dose of
75 mg/kg Ara-C in h-leukemic NOG mice significantly reduced
leukemic cell numbers in PB (Figure 6A). Pathological analysis of
the liver showed that leukemic cells accumulating around the
portal area markedly decreased after 4 days of Ara-C treatment.
However only a few remaining leukemic cells were observed
mainly next to bile duct epithelial cells (Figure 6B). A cell cycle
analysis of leukemic cells in the liver before and after Ara-C
treatment revealed that the leukemic cells in the G2/M-phase of
the cell cycle were preferentially eliminated, and that this was
accompanied by the enrichment of the quiescent clones after
chemotherapy (Figure S5). Within 3 weeks after treatment, the
number of ALL cells returned to pre-treatment levels in the PB.
We used this protocol as a model for chemotherapy-induced
remission and recurrence.
To elucidate the effect of SDF-1/CXCR4 axis on leukemic cell
clusters regrowth in the liver portal areas, we treated h-leukemic
NOG mice with Ara-C and subsequently with AMD3100 or NS
for seven days (Figure 6C). In control mice receiving NS, leukemic
cell regrowth in the liver was observed primarily in the portal area
by day 7 (Figure 6D, left panel). In contrast, in the treatment
group receiving AMD3100, leukemic cell cluster regrowth was
Figure 5. The signaling via SDF-1/CXCR4 axis stimulates migration and proliferation of leukemic cells. (A) Leukemic cells were plated
onto upper chamber of transwell plates with 250 ng/ml SDF-1a in lower chamber, in presence or absence of AMD 3100 pretreatment. Results
expressed as percentage of migrating cells to input cell number. (*P=0.014, Student’s t- test, n=4). (B) Methylcellulose colony-forming assay to
evaluate effect of SDF-1/CXCR4 signaling on leukemic cell proliferation. Addition of SDF-1a significantly increased leukemic colony numbers, and
treatment with AMD3100 counteracted effect of SDF-1a (*P=0.0019, Student’s t-test, n=3). (C) Phosphorylation of ERK1/2 (pERK1/2) and Akt (pAkt)
was detected by Western blot analysis. b-actin was used as a loading control. (D) Sequential FACS analyses showing bone marrow engraftment after
transplantation of leukemic cells harvested from BM and liver of ALL leukemic cell-transplanted mice. Graphs show percentage of blast cells in
recipient BM (*P=0.0048, Student’s t- test, n=428 mice per case). Data are shown as means6S.D.
doi:10.1371/journal.pone.0027042.g005
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macroscopic size of the liver and spleen in AMD3100-treated
leukemic mice was smaller than that in control mice (Figure 6E),
and leukemic cell counts and organ volumes of the liver and spleen
were significantly reduced (Figure S6). Interestingly, the largest
decrease in leukemic cell count was observed in the liver of
AMD3100-treated mice (Figure 6F), and was seemingly correlated
to the frequency of CXCR4-positive leukemic cells in each organ
(see Figure 4A). During the long-term administration of AMD3100
or NS up to 60 days after AraC treatment, significantly fewer
leukemic cells were present in the PB of AMD3100-treated mice
compared with control mice receiving NS (Figure 6G). Conse-
quently, the control mice lost a significant amount of body weight,
while the body weight of the AMD3100-treated mice was not
significantly different compared with that of normal NOG mice
(Figure S7). Furthermore, the AMD3100-treated mice demon-
strated a higher overall survival, as estimated by the Kaplan-Meier
method (Figure 6H).
Overall, these results strongly indicate that the SDF-1/CXCR4
signaling pathway plays a crucial role in re-expansion of ALL
leukemic cells in the hepatic niche after chemotherapy and
provide a novel anti-leukemic therapy that targets the extramed-
ullary microenvironment.
Discussion
In this paper, we propose that leukemic extramedullary
pathology is due to not only migrating, but also resident
proliferating leukemic cells in the extramedullary niche. Using
xeno-transplantation model, previous reports showed that human
leukemic cells infiltrate the liver [13,14]; however, those reports
lacked pathological or molecular assessment. Here, through the
analysis of h-leukemic NOG model, we have demonstrated that
hepatic extramedullary microenvironments provide a niche which
harbors and propagates leukemic cells.
We also demonstrated that the SDF-1/CXCR4 axis plays a
crucial role incausing liver pathology.Recent studies revealed SDF-
1/CXCR4 axis involvement in the development and metastasis of
solid tumor [18,19]. This axis has also been known to play an
indispensable role in the homing, proliferation, and survival of both
normal hematopoietic and leukemic cells in the BM niche
[18,29,30,31,32,33,34,35]. In pediatric ALL patients, high expres-
sion of CXCR4 in leukemic cells was strongly predictive of
extramedullary organ involvement [34], which is compatible with
the findings in our murine xeno-transplantation model. By
analyzing the detailed structure of the hepatic niche, we found that
certain extramedullary niche was also dependent on SDF-1/
CXCR4 axis for recruitment and proliferation of leukemic cells.
We showed that leukemic cells in the peripheral blood were
predominantly non-proliferating, although the BM and liver
contain a large proportion of proliferating leukemic cells. These
findings indicate that leukemic cells can proliferate efficiently in
medullary/extramedullary sites if proper microenviromental
conditions are provided, but cannot in the peripheral blood where
microenviromental structure is absent. This finding is also
compatible with the observation that in vitro cultures of
lymphoblastic leukemic cells are more difficult to achieve in
floating conditions, like in peripheral blood, than on stromal cell
layers, like cells in medullary/extramedullary microenvironment
[36].
In our therapeutic model, AMD3100 prevented extramedullary
regrowth of leukemic cells after chemotherapy and dramatically
improved the overall survival. Importantly, without AMD3100
administration, a few leukemic cells remaining in the portal region
after chemotherapy appeared to contributed to the regrowth of
leukemia. We speculate that two reasons may account for this
extramedullary regrowth of leukemic cells. First, chemotherapy
resistance may be induced by epithelial cells in the portal areas. In
the BM, direct contact between ALL leukemic cells and stromal
cells is one of the important mechanisms to induce drug resistance
for leukemic cells [25]. Thus, it is very likely that leukemic cells
next to hepatic niche cells can survive chemotherapy in an
analogous manner. Second, a more fundamental reason is derived
from the concept of the leukemic stem cells which have potency to
regenerate leukemia [37] and contribute to relapse [5]. In acute
myeloid leukemia (AML) in the BM, CD34-positive leukemic stem
cells contribute to AML relapse by homing in on and expanding
within the niche usually occupied by normal hematopoietic stem
cells [5]. Furthermore, it has recently been shown that Ara-C
treatment specifically targeted proliferating cells in an AML
xenograft model, resulting in the enrichment of quiescent leukemic
stem cells in the G0/G1 phase of the cell cycle, thereby
contributing to disease relapse [38]. Our current data also showed
that quiescent clones were not affected by chemotherapy, and
thereby subsequently contribute to disease recurrence. Interest-
ingly, during liver regeneration, the portal area serves as an
important niche for both oval cells and migrating hematopoietic
stem cells [10,15,39]. If ALL cells arise via a leukemic stem cell
hierarchy similar to AML [37], this hepatic niche may serve as a
haven for leukemic stem cell survival and proliferation. Consid-
ering the aforementioned reasons for the persistent presence of
leukemic cells, extramedullary niche-targeting therapy could be a
powerful option for preventing recurrence in extramedullary
organs as well as the BM.
In conclusion, using the h-leukemic NOG model, we demon-
strated that the extramedullary dissemination of leukemia is not
due to nonselective infiltration, but rather systematic invasion and
proliferation of leukemic cells in a particular niche at extramed-
ullary sites. Because various signals from the leukemic niche may
contribute to the progression of leukemia, future studies that
Figure 6. AMD3100 inhibited the in vivo dissemination of leukemic cells surrounding the bile ducts after chemotherapy, thus
leading to the superior survival of h-leukemic NOG mice. (A) Ara-C was administered i.p. to leukemic mice, and leukemic cell counts per mlP B
were monitored every three days. (B) H–E staining of leukemic liver sections before (day 0, left panel) and after (day 4, right panel) Ara-C treatment.
Scale bar, 100 mm (C) Schematic of AMD3100 and normal saline (NS) injection for leukemic mice following Ara-C treatment. (D) Administration of
AMD3100 resulted in reduction of leukemic cell cluster regrowth in portal areas compared with administration of NS (i).A few leukemic cells observed
in the sinusoidal area in both groups (ii). pv; portal vein. Arrowheads indicate bile ducts. Scale bar, 100 mm. (E) Representative macroscopic
appearance of liver and spleen in leukemic mice after AMD3100 administration. Vehicle alone group is on the left-hand side and AMD3100 injected
group is on the right-hand side. Scale bar, 1 cm. (F) Percentage of leukemic cells in the BM, liver and spleen of AMD3100-treated leukemic mice
compared with that of control mice. Average number of leukemic cells harvested from each organ of vehicle-injected mice was set as 100 (*P=0.039,
Student’s t- test, compared with BM, n=5 per condition).Data are shown as mean6 S.D. (G) AMD3100 or NS was administered for up to 60 days to h-
leukemic NOG mice after chemotherapy. The leukemic cell counts in the PB were monitored every ten days beginning 4 days after the chemotherapy.
AMD3100 after chemotherapy prevented the recurrence of leukemia in vivo (P,0.01 on days 14 and 24). (H) The AMD3100-treated mice (n=5)
demonstrated a higher overall survival than the control mice receiving NS (n=4), as estimated by the Kaplan-Meier method (P=0.0221 for
comparisons of the h-leukemic NOG mice treated with AMD3100 and NS).
doi:10.1371/journal.pone.0027042.g006
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necessary for developing novel niche-targeted therapeutics.
Materials and Methods
Mice
NOG mice were developed at the Central Institute of
Experimental Animals (Kawasaki, Japan), as previously de-
scribed[9]. All mice were kept under specific pathogen-free
conditions in accordance with the guidelines of the facility.
Human samples
BM samples were collected from patients with pediatric ALL at
the time of diagnosis with written informed consent under the
guidelines of the institutional ethics committee, Kyoto University
Graduate School and Faculty of Medicine, Ethics Committee
(approval ID is G-283). Mononuclear cells were separated by
Ficoll-Hypaque density gradient centrifugation soon after aspira-
tion.
Primary and serial xenogeneic transplantation of ALL
cells into NOG mice
Xeno-transplantation and analysis of ALL cells were performed
by modifying previously reported methods[8]. In brief, leukemic
cells (1610
6cells) were transplanted into non-pretreated 8- to 10-
week old NOG mice by the tail vein or via intra-femoral injection.
For serial transplantation, leukemic cells were obtained from the
recipient BM and intravenously transplanted into non-pretreated
NOG mice via the tail vein.
Flow cytometric analysis of mice with transplanted
leukemic cells
For analysis of leukemic cells in organs, mice were sacrificed by
cervical dislocation at the indicated times after transplantation.
After as much peripheral blood was collected as possible, the BM,
liver and spleen were removed and mechanically dispersed.
Samples from each organ were stained with antibodies after
isolation of mononuclear cells. Dead cells were excluded by 49-6-
Diamidino-2-phenylindole (DAPI) staining. Samples were ana-
lyzed using a FACS LSR and Cell Quest software (Becton
Dickinson) according to the manufacturer’s protocol. Antibodies
used for flow cytometric analysis were anti-human CD45-
allophycocyanin (APC) (BD Pharmingen), anti-human N-CAM-
APC (BD Pharmingen), anti-mouse CD45-APC (BD Pharmin-
gen), anti-human CD19-phycoerythrin (PE) (eBiosciences), anti-
human CXCR4-PE (BD Pharmingen), anti-human CD44-PE
(BD Pharmingen), anti-human very late antigen-4 (VLA-4)-PE
(BD Pharmingen), anti-human CC chemokine receptor 7
(CCR7)-PE (R&D Systems), anti-human CD45-fluorescein iso-
thiocyanate (FITC) (BD Biosciences), and anti-human CD19-
FITC (Dako).
Histological analysis of patient and mouse samples
The histological analysis of patient samples and mouse BM was
performed by May-Grunwald Giemsa staining of cytospine
preparations using standard procedures. Hematoxylin-Eosin (H-
E) staining was performed on tissue sections derived from the
recipient mice. Detection of human leukemic cells in the murine
organs by immunohistochemical analysis was performed using a
previously reported method[10]. The antibodies (and dilutions)
used were mouse anti-human CD45 (1:100) (DAKO), mouse anti-
human/mouse CXCL12/SDF-1a antibody (1:100) (R&D Sys-
tems), rabbit polyclonal CXCR4 (Abcam) and Cy3-conjugated
donkey anti-mouse IgG or FITC-conjugated donkey anti-rabbit
IgG at a dilution of 1:100 (both from Jackson ImmunoResearch
Laboratories). Hoechst 33324 (Invitrogen) was used for nuclear
staining. Prepared samples were then examined under a light or
fluorescence microscope (Olympus).
5-bromo-2-deoxyuridine (BrdU) staining
In vivo BrdU labeling was performed by injecting leukemic mice
with 0.2 ml BrdU (5 mg/ml, Sigma) intraperitoneally three times
at 4, 24, and 48 h before analysis. Immunohistochemical staining
of BrdU was performed using a BrdU staining kit (Invitrogen)
according to the manufacturer’s protocol.
Cell cycle analysis
For quantification of cells in the S/G2/M phase of the cell
cycle, ALL-engrafted recipient BM, peripheral blood, and liver
oriented leukemia cells were labeled with Hoechst 33342 and
pyronin Y, or Propidium Iodide (PI) using standard procedures.
Samples were analyzed using FACS LSR and Cell Quest software
(Becton Dickinson).
Migration assay
A total of 5610
5 cells in a volume of 0.5 mL were added to the
top chamber of 24 well MULTIWELL
TM plates (Becton
Dickinson). The wells separate cells using a polycarbonate
membrane filter (3.0 mm pore size) from a lower compartment
containing 0.5 mL RPMI with 10% FCS containing 250 ng/ml
SDF-1a (R&D Systems). Chemotaxis assays were conducted at
37uC for 4 h. Some assays were performed using leukemic cells
preincubated for 30 min at 37uC in the presence of AMD3100
(0.1 mg/ml) (Sigma).
Colony assays
Colony assays were performed by modifying a previously
reported method[40]. Leukemic cells were incubated in a
methylcellulose culture dish at a concentration of 1610
6 cells/
mL. Some experiments were performed on leukemic cells
preincubated for 30 min at 37uC in the presence of AMD3100
(0.1 mg/ml) before the colony assays. SDF-1a (R&D Systems) was
added to the control cytokines at a concentration of 250 ng/ml.
Colonies were harvested, washed twice and cytospine stained with
May-Grunwald Giemsa stains to identify leukemic cells.
Western blot analysis
A total of 5610
5 leukemic cells were pretreated for 30 min at
37uC in the presence or absence of AMD3100 (0.1 mg/ml) and
then incubated with or without 100 ng/mL SDF-1a for 5 minute.
After that, cells were lysed in ice-cold lysis buffer (Thermo
Scientific) supplemented with a protease inhibitor cocktail (Nacalai
tesque). Lysates were then separated on a 10% polyacrylamide gel,
transferred to Immobilon-P membranes (Millipore), probed with
the appropriate antibodies (anti–human AKT, Ser 473–phosphor-
ylated AKT, ERK, phosphorylated ERK , b-Actin from Cell
Signaling Technologies), and visualized using an enhanced
chemiluminescence (ECL) plus kit (GE Healthcare).
Cytosine arabinoside (Ara-C) treatment and AMD3100
administration
Intraperitoneal (i.p.) injection of 75 mg/kg Ara-C (Sigma) was
performed in NOG recipients transplanted with leukemic cells.
AMD3100 (Sigma) was administered intraperitoneally at a dose of
200 mg for 7 days or up to 60 days in the long-term assay starting
the day after Ara-C injection.
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Statistical comparisons between experimental groups were
analyzed using the Student’s t-test or paired t-test, and for all
comparisons a P value less than .05 was considered significant.
Supporting Information
Figure S1 NOG mice support efficient human primary
ALL engraftment without pre-conditioning. Primary hu-
man ALL engraftment in NOG mice injected with 1610
6
BMMNCs from nine ALL patients. Percentage of human ALL
cells (hCD45+ or hCD19+ cells) in recipient BM determined one
to five months post-injection. Numbers in circles indicate case
number and show mean percentage of ALL cells in recipient BM
in each cases (n=126 mice per case).
(TIF)
Figure S2 BM, liver and spleen contain plenty of
leukemic cells. Pale BM, enlarged liver and spleen were
massively infiltrated with leukemic cells. Histologically, no specific
sites of infiltration were observed in the spleens of the transplanted
NOG mice. Scale bar, 50 mm.
(TIFF)
Figure S3 The actual interaction between CXCR4 on
leukemic cells and SDF1. Representative images of Proximity
Ligation Analysis (PLA) detected by the Duolink Detection kit
(Olink Bioscience, Uppsala, Sweden). The system elicits a visible
signal only when the two antibodies (i.e. anti-SDF-1 and anti-
CXCR4) are in close proximity. Arrows denote regions of signal
amplification indicating the actual interaction between SDF-1 and
CXCR4. Nuclear stain is DAPI (Blue). Scale bar indicates 50 mm.
(TIF)
Figure S4 The checker board assay. Increasing concentra-
tions of SDF-1a were added to upper or lower compartments of
migration chambers. Significant increases in numbers of migrating
cells were observed when reagent was added to lower chambers.
Baseline was defined as result of assay without SDF-1a. Increasing
concentrations of SDF-1a were added to upper or lower
compartments of migration chambers. Significant increases in
numbers of migrating cells were observed when reagent was added
to lower chambers. Baseline was defined as result of assay without
SDF-1a.
(TIF)
Figure S5 AraC preferentially eliminates cycling leuke-
mic cells in vivo. The cell cycle analysis of leukemic cells
harvested from the liver before and after AraC treatment (80 mg/
mice). The liver-oriented leukemic cells in the G2/M-phase of the
cell cycle were preferentially eliminated, and the quiescent clones
were not affected by the chemotherapy.
(TIF)
Figure S6 AMD3100 inhibits hepatosplenomegaly. Leu-
kemic cell numbers (A) and weights of livers and spleens (B) from
leukemic mice treated with vehicle alone (saline) or AMD3100
after Ara-C treatment. Each graph shows mean cell numbers and
weights (* P,0.05. Student’s t- test, n=5 per condition). Data are
shown as means6S.D.
(TIF)
Figure S7 Administration of AMD3100 after chemother-
apy prevented the recurrence of leukemia in vivo.
Control mice receiving NS experienced relapsed leukemia and
lost significant body weight compared with AMD3100-treated
mice (P,0.01. Student’s t- test, n=425 per condition) and age-
matched normal NOG mice (P,0.01). On the other hand, the
body weight of the AMD3100-treated mice was not significantly
different in comparison to that of the age-matched normal NOG
mice.
(TIF)
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